Ortho’s purpose is to improve and save lives with diagnostics. Ortho does that by reimagining what’s possible.

Headquartered in the U.S., the company’s 4,400 global employees serve customers in more than 125 countries and territories. Ortho ramped up investment in R&D (nearly $100 million annually, or more than 5% of sales), launched next-generation instruments for the Immunohematology and Clinical Labs markets and, by the end of 2018, will have launched more than 60 new or enhanced assays since becoming independent in 2014.

Innovation

In July 2018, Ortho achieved CE Mark for its VITROS® XT 7600 Integrated System, an automated, next-generation analyzer that detects diseases, conditions, and substances in the blood. Like other analyzers in Ortho’s VITROS portfolio, the VITROS XT uses the company’s proprietary dry slide technology, which does not require water or plumbing to operate.

Earlier this year, Ortho launched the VITROS® HIV Combo Test on its VITROS® 3600 analyzer in the U.S. HIV Combo is an innovative new test for HIV that enables disease detection earlier than previous generations of tests. Ortho also launched VITROS® NEPHROCHECK®1, the first automated test that can predict risk of deadly acute kidney injury in time for meaningful medical interventions to take place.

The company’s ORTHO VISION® and ORTHO VISION® Max analyzers bring automation to immunohematology—helping labs run more efficiently and effectively.

Talent Development

The company was recently recognized as a Great Place to Work by the Great Place to Work® Institute in India.

98% of legacy employees followed Ortho as it became an independent company in 2014. Ortho has since added more than 2,200 employees.

Social Responsibility

Ortho’s Rochester, NY, manufacturing and R&D facilities saw a 26% reduction in water consumption from 2015 to 2017.

The company’s Pencoed, Wales, site in the U.K. achieved zero landfill status in 2016 and 2017.

Ortho’s VITROS® systems for the clinical lab do not require water or plumbing to run. The importance of this to the developing world, where water scarcity is often an issue and the likelihood of poor water quality is high and could affect test results, is clear. It’s why Ortho’s products are used on everything from aircraft carriers to humanitarian aid ships around the world.

PM360 embraces diversity, gender equality, ideas, and innovation that advance bold ideas in pharmaceutical marketing. PM360 is the premier magazine for marketing decision makers in the pharmaceutical, biotech, and medical device industries. Published monthly, PM360 is the only journal that focuses on delivering the full spectrum of practical information necessary for product managers and pharma marketing professionals to succeed in the complex healthcare environment.